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ABSTRACT
Depression is common among women with HIV and untreated depression can result in poor
quality of life and worsen HIV outcomes. Women with HIV who are dually enrolled in Medicaid
and Medicare faced a potential disruption in medication access when Medicare Part D was
implemented in 2006. The goal of this study was to estimate the effects of Medicare Part D
implementation on antidepressant use, depressive symptoms, and hospitalization in Medicaid-
Medicare dual eligible women with HIV. This study used 2003–2008 data from the Women’s
Interagency HIV Study. The effects of Medicare Part D were estimated using a difference-in-
differences approach, adjusting for temporal trends using a matched control group of
Medicaid-only enrollees. Before Medicare Part D implementation, dual eligibles differed from
Medicaid-only enrollees in antidepressant use and hospitalization, despite having identical
prescription drug coverage through Medicaid. For dual enrollees, the transition to Medicare
Part D was not associated with changes in antidepressant use, depressive symptoms, or
hospitalization. We did not find disruptive effects on antidepressant use and related outcomes
among dual eligibles in this study. Stable antidepressant use may be due to better access to
medical care for dual eligibles through Medicare both before and after Medicare Part D
implementation, which may have eclipsed any effects of the transition. It may also signal that
classification of antidepressants as a protected drug class under Medicare Part D was effective
in preventing psychiatric medication disruption.
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Introduction
Depression is the most common psychiatric comorbidity
in people with HIV in the United States (Lopes et al.,
2012). Untreated depressive symptoms have been associ-
ated with reduced antiretroviral therapy (ART) adher-
ence (Bouhnik et al., 2005; Horberg et al., 2008; Lima
et al., 2007), unsuppressed HIV viral load (Evans et al.,
2002; Leserman, 2008), and shortened survival (Cook
et al., 2004). Sub-optimal ART adherence has also been
shown to increase the risk of hospitalization in women
with HIV (Fielden et al., 2008). By contrast, people
with HIV who are treated for depression showed similar
ART adherence and HIV viral control to people with
HIV who did not have depression (Horberg et al.,
2008), highlighting psychiatric medications as an inter-
vention to lessen depression, decrease hospitalization,
and improve HIV outcomes.
For many people with HIV, health insurance facilitates
access to prescription drugs, such as antidepressants, by
reducing or eliminating costs of obtaining therapy
(Gebo et al., 2010). Most people with HIV rely on public
insurance programs for their health insurance coverage,
with 56% receiving coverage through Medicaid or Medi-
care (Yehia et al., 2014). Medicare provides health insur-
ance to Americans age 65 and over, as well as to
persons under the age of 65 with disabilities (The Henry
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J. Kaiser Family Foundation, 2012). Medicaid has tra-
ditionally provided health insurance to certain categories
of low-income persons (Kaiser Family Foundation,
2013). Of adults with HIV who were enrolled inMedicaid,
31% met eligibility criteria for Medicare and Medicaid in
2007, and were enrolled in both programs (“dual eli-
gibles”) (Young, Garfield, Musumeci, Clemans-Cope, &
Lawton, 2013). For dual eligibles, Medicare provides pri-
mary coverage while Medicaid absorbs the remaining
costs and also provides primary coverage for services
not available through Medicare (Young et al., 2013).
Before 2006, Medicare did not include an outpatient
prescription drug benefit and dual eligibles received pre-
scription drug coverage through Medicaid’s drug benefit.
On 1 January 2006, Medicare implemented its own pre-
scription drug benefit, Medicare Part D, and required
dual eligibles to transition their prescription drug cover-
age from Medicaid to Medicare Part D (United States
Government Accountability Office, 2007). The goal of
Medicare Part D was to improve medication access by
reducing financial barriers for Medicare enrollees need-
ing prescription drugs. Although a review associated
Medicare Part D implementation with increased medi-
cation use and decreased out-of-pocket costs in the gen-
eral Medicare population, its effects on dual eligibles and
other vulnerable populations were mixed (Polinski, Kila-
buk, Schneeweiss, Brennan, & Shrank, 2010). In the tran-
sition to Medicare Part D, dual eligible beneficiaries were
randomly assigned to prescription drug plans that,
within general guidelines, determined their own formul-
aries and medication access rules, which often varied
widely by plan. Further, cost-sharing for prescription
drugs was mandated under Medicare Part D (Kaiser
Family Foundation, 2006). By contrast, Medicaid’s pre-
scription drug benefit had a broader benefits package,
only allowed nominal cost-sharing (Crowley & Ashner,
2005), and included protections that allow enrollees to
receive their prescriptions without co-payment if they
were unable to pay (Kaiser Family Foundation, 2006).
Cost-sharing and medication disruptions are of
special concern for dual eligibles with mental health con-
ditions because of limited ability to pay for medications
and because disruptions can have adverse consequences
for symptom occurrences and health service utilization
(Morden & Garrison, 2006). Two studies examined the
effects of Medicare Part D on dual eligibles with psychia-
tric conditions shortly after implementation (Huskamp
et al., 2009; West et al., 2010). In the first study, psychia-
trists indicated that 44% of dual eligible patients had
difficulties accessing a psychiatric medication (Huskamp
et al., 2009). The second study demonstrated that medi-
cation access problems for dual eligibles with psychiatric
conditions increased slightly during the first year after
Medicare Part D implementation (West et al., 2010).
These studies indicated that Medicare Part D was associ-
ated with financial and administrative barriers to medi-
cation access for dual eligibles with psychiatric
conditions, and that those barriers were sustained over
at least the first year after implementation.
Thirty-five percent of dual eligibles with psychiatric
conditions were unable to access their medication after
Medicare Part D implementation because the medication
was not covered by their Medicare Part D plan (Hus-
kamp et al., 2009). In a similar population of dual eli-
gibles with psychiatric conditions, 29% discontinued or
temporarily stopped their medication because of cover-
age limitations (West et al., 2010). Increased switching
following Medicare Part D implementation may have
adversely affected mental health outcomes because psy-
chotropic drugs classes are less therapeutically inter-
changeable than medications for other chronic
conditions (Goldman et al., 2004). Prescription drug
plans within Medicare have shown variable medication
switching rates, indicating that some plans may be
more appropriate for dual eligibles with psychiatric con-
ditions (Donohue & Frank, 2007; Huskamp, 2003).
Given indications of increased cost-sharing, variation
in prescription drug plan formularies, and reports of psy-
chiatric medication disruption associated with Medicare
Part D among dual eligibles, the goal of this study was to
estimate the effects of Medicare Part D implementation
on antidepressant use, depressive symptoms, and hospi-
talization among women with HIV. We used six years of
data from the Women’s Interagency HIV Study (WIHS),
an observational cohort investigating the treatment and
prevention of HIV infection in women.
Methods
Data source
The WIHS prospectively studies women who are living
with or at high risk for HIV infection (Barkan et al., 1998;
Hessol et al., 2009). Since 1994, the WIHS has collected
data biannually on 3677 women living with HIV. We
used six years of data from study visits between 2003 and
2008. During that timeframe, the WIHS consisted of six
study sites, located in the Bronx, NY; Brooklyn, NY;
Washington, DC; San Francisco, CA; Los Angeles, CA;
and Chicago, IL. Study visits include a physical examin-
ation, laboratorymeasurements, and an interview to obtain
insurance,medication, and sociodemographic information.
Design and study sample
This study is a secondary data analysis of WIHS partici-
pants who attended study visits between 2003 and 2008
(N = 1,807). We restricted our study to participants who
(1) were living with HIV in 2003 and (2) reported Med-
icaid-Medicare dual eligibility or Medicaid-only enroll-
ment in 2005. Participants who missed three
consecutive visits between 2003 and 2008 were excluded
from this analysis to ensure representation in both pre-
and post-implementation time periods. There were 125
dual eligibles (67% of all dual eligibles in 2005) and
676 Medicaid-only participants (77% of all Medicaid-




To control for temporal trends in medication use that are
unrelated to Medicare Part D implementation, we com-
pared individuals who were on Medicaid only before and
after January 2006 to those who transitioned from Med-
icaid to Medicare Part D’s prescription drug coverage
during the same period. We categorized participants
into two mutually exclusive groups. Participants who
were dual eligibles at any point in 2005 were considered
dual eligible at the transition to Medicare Part D, and
made up our analytic group of interest. Participants
who reported Medicaid coverage and no other private
or public insurance in 2005 were considered Medicaid-
only at the transition to Medicare Part D, and made up
our matched control group.
Outcomes of interest
The following self-reported outcomes were examined:
(1) antidepressant use, (2) depressive symptoms, and
(3) inpatient hospitalization.
We examined pharmacologic treatment of depression
by assessing the proportion of participants who self-
reported taking “medication for psychological conditions
or depression” since their last study visit, taken as a
proxy for antidepressant use in the last six months and
created a binary indicator variable.
Depressive symptoms were assessed at each visit using
the Center for Epidemiologic Studies Depression Scale
(CES-D) (Radloff, 1977). First, we treated this outcome
continuously, with scores ranging from 0 to 60. Second,
we created a binary indicator of probable depression,
where participants were classified as having probable
depression if their CES-D score was ≥16 and as not hav-
ing probable depression otherwise (Radloff & Locke,
1986). Finally, we assessed self-reported, inpatient hospi-
talization. In addition to a binary indicator of any hospi-
talization in the six months since the previous study visit,
we also assessed the number of hospitalizations.
Statistical analysis
Using the raw data, we plotted each of our outcome vari-
ables for visits between 2003 and 2008 using a segmented
locally weighted smoothed spline (Lowess) plot (Cleve-
land, 1979) to visualize discontinuities associated with
the transition and to support the validity of a differ-
ence-in-differences analysis by demonstrating that the
parallel trends assumption holds.
Propensity score matching. An unadjusted comparison
between dual eligibles and the Medicaid-only group
could be confounded by inherent differences between
the two groups, we used propensity scores to match
dual eligibles with study participants who were enrolled
in Medicaid only.
Propensity scores were created using logistic
regression, where dual eligibility was a function of the
pre-treatment covariates. After estimating the propensity
scores, dual eligibles were matched 1:1 with Medicaid-
only participants using a nearest-neighbor matching
approach, without replacement (Morgan & Harding,
2006). Of the baseline (pre-Medicare Part D) variables
considered for the propensity score model, our final set
included: race (African-American vs. other), HIV viral
load, age, hospitalization, any antidepressant use, and
total number of medications (ART and other). As con-
tinuous variables, age and HIV viral load were included
as splines (Royston & Sauerbrei, 2007), and categorical
variables were dichotomized. We used Stata’s psmatch2
program to match the groups by propensity score (Leu-
ven & Sianesi, 2014) and mkspline to create restricted
cubic splines (Stata Corp., n.d.; Nichols, 2007). We com-
pare covariate balance pre- and post-propensity score
matched groups in Table 1.
We used a difference-in-differences (DiD) approach
on the propensity score-matched cohort to estimate the
effects of Medicare Part D implementation on dual eli-
gibles with HIV. The Medicaid-only comparison group
allowed us to control for temporal trends (e.g., advances
in ART or antidepressants) that were common to both
groups. The DiD approach consists of a linear model
with an interaction term for insurance group (dual eli-
gible or Medicaid-only) and time period (pre- or post-
Medicare Part D). The approach allowed us to compare
the average changes in proportions between pre- and
post- Medicare Part D in dual eligibles (the group that
was affected by Medicare Part D implementation) to
the average changes in proportions between pre- and
post-Medicare Part D in participants with Medicaid
only (the group that was unaffected by Medicare Part
D implementation). The resulting “difference-in-differ-
ences” can be attributed to the policy change, if both
groups have parallel trends in the pre-Medicare Part D
time period, known as the parallel trends assumption
(Stuart et al., 2014).
Finally, sensitivity analyses assessed the robustness of
the results to the length of the time period analyzed
(comparing 1, 2, or 3 years on either side of Medicare
Part D implementation) and to propensity score match-
ing approaches (nearest neighbor, kernel, 1:1). Study
results remained consistent when we explored abbre-
viated lengths of time before and after Medicare Part D
implementation, as well as a range of propensity score
model specifications. All statistical analyses were per-
formed using Stata 13 (StataCorp, College Station, TX).
Results
Eight hundred and one women met the inclusion cri-
teria, of whom 125 (16%) were dual eligibles and 676
(84%) were Medicaid-only (Table 1). Before propensity
score matching, dual eligibles differed from Medicaid-
only participants by age, race, education, WIHS site,
out-of-pocket prescription drug spending, antidepress-
ant use, hospitalization, and HIV viral suppression.
The median age of dual eligibles was higher (47 years;
interquartile range [IQR]: 41–52) than Medicaid-only
participants (43; IQR: 38–49). Fewer dual eligibles were
African-American compared to Medicaid-only
participants (57% vs. 68%). A greater proportion of
dual eligibles completed high school or higher levels of
education compared to Medicaid-only participants
(74% vs. 48%). Annual household income was low over-
all; two-thirds of participants (66%) earned less than
$12,000 annually with 21% earning less than $6,000
(result not shown). Despite higher household income,
greater education levels, and higher prevalence of HIV
viral suppression, a larger proportion of dual eligibles
reported being hospitalized in the past six months
(24%) compared to Medicaid-only participants (17%).
There was a striking difference in antidepressant use
between dual eligibles and Medicaid-only participants
in 2005. Over 38% of dual eligibles reported antidepress-
ant use compared to 18% of Medicaid-only participants.
This finding was more pronounced in dual eligibles with
probable depression (CESD≥ 16), of whom 49% were
taking antidepressants compared to 25% of Medicaid-
only participants with probable depression (result not
shown). Despite different levels of antidepressant use,
dual eligibles and Medicaid-only participants had similar
levels of depressive symptoms as both groups had a
median CES-D score of 14 and similar IQRs.
Before propensity score matching, we created Lowess
plots for all outcomes to visualize trend breaks associated
with Medicare Part D implementation and to provide













(n = 117) p-valuea
Age, median (IQR) 47 (41, 52) 43 (38, 49) <0.01 46 (41, 52) 46 (41, 51) 0.79
African American, % 56.5 67.9 0.01 59.4 59.4 1.00
Hispanic Ethnicity, % 24.2 26.6 0.58 23.2 31.0 0.15
WIHS Site, %
Bronx 15.2 28.7 <0.01 15.3 40.2 <0.01
Brooklyn 20.0 23.5 0.39 22.4 19.7 0.75
Washington, DC 8.0 8.6 0.83 7.7 5.1 0.43
Los Angeles 20.0 11.0 <0.01 18.8 7.7 0.01
San Francisco 24.0 15.1 0.01 23.1 15.4 0.14
Chicago 12.8 13.2 0.91 13.7 12.0 0.67
Out-of-pocket prescription drug spending, % 22.8 12.9 <0.01 22.6 14.8 0.13
100% ART adherentb 51.2 43.2 0.13 52.6 48.4 0.56
Antidepressant use, % 38.2 18.4 <0.01 37.6 35.9 0.79
CES-D score, median (IQR) 14 (3.5, 28.5) 15 (6, 25) 0.84 14 (6, 24) 14 (4, 29) 0.85
Hospitalized in past six months, % 23.5 17.2 0.02 19.7 17.9 0.74
Annual household income <$12,000/year, % 62.4 67.1 0.32 62.9 70.0 0.29
Education, %
Less than high school 25.6 51.9 <0.01 25.0 23.3 0.76
Employed, % 12.9 18.6 0.13 11.2 12.9 0.69
CD4 cell count, median (IQR) 466 (312, 643) 416 (249, 622) 0.27 422 (291, 643) 452 (279, 644) 0.89
Suppressed HIV VLc, % 59.3 48.0 0.02 56.5 60.9 0.51
Abbreviations: ART, antiretroviral therapy; CES-D, Center for Epidemiologic Studies Depression Scale; IQR, interquartile range; HIV, Human Immunodeficiency
Virus; VL, viral load.
aStatistical significance tested using t tests and chi-square tests for continuous and categorical/binary variables, respectively.
bProportions calculated within subset on ART, where 100% ART adherence is defined as the proportion of time that antiretrovirals were taken as prescribed over
the past six months.
cSuppressed HIV viral load corresponds to a viral load measurement of <200 copies/mL.
graphical support for the parallel trend assumption
(Figure 1, panels A–C). Lowess plots indicated that the
parallel trend assumption held for all outcomes and sup-
ported the validity of the DiD analyses. Lowess plots did
not indicate a trend break for any outcome with dual eli-
gible participants, although for the control group of
Medicaid-only enrollees, there appeared to be increased
antidepressant use. After matching on propensity scores,
our sample was limited to 117 dual eligibles (94% of the
125 participants who were dual eligible in 2005) whose
propensity scores were within the range of the propensity
scores of the control group, and a matched group of 117
Medicaid-only participants.
Within the matched cohort, we estimated the DiD for
all outcomes and obtained the average changes in pro-
portions among dual eligibles between the two time
periods, adjusted for temporal trends (Table 2). After
accounting for temporal trends by subtracting the esti-
mates in the matched control group, the implementation
of Medicare Part D did not have an impact on dual eli-
gibles’ antidepressant use, depressive symptoms, or inpa-
tient hospitalization.
Discussion
This study yielded several key findings. First, the
unmatched, unadjusted comparison between dual eli-
gibles and Medicaid-only participants showed that, in
2005, antidepressant use was significantly higher
among dual eligibles than among participants with Med-
icaid only (38% vs. 18%), despite similar levels of
depressive symptoms. Further, a greater proportion of
dual eligibles with probable depression reported anti-
depressant use in 2005 compared to Medicaid-only par-
ticipants with probable depression (49% vs. 25%).
However, both groups received prescription drug cover-
age through Medicaid in 2005, making it unlikely that
prescription drug coverage characteristics (formularies,
utilization management tools, etc.) are responsible for
this difference in antidepressant use.
There are several possible explanations for these
findings given the same prescription drug coverage
between the two groups before Medicare Part D
implementation was similar. First, there were several
other differences between dual eligibles and Medicaid-
Figure 1. Changes in proportions of outcomes of interest, by insurance type and time period, in the Women’s Interagency HIV Study
(WIHS), 2003–2008.
only enrollees in 2005 (age, race, education, hospitaliz-
ation, HIV viral suppression, and WIHS site). However,
the association between insurance type and antidepress-
ant use remained after adjustment for the variables
above. Second, people with psychotropic medication
needs may be more likely to become Medicare enrollees
through a mental health-related disability. Third,
although dual eligibles received prescription drug cover-
age through Medicaid before 2006, they were still receiv-
ing medical coverage through Medicare. Dual eligibles
may access medical care more easily than Medicaid
enrollees; access to care rather than prescription drug
coverage may have determined antidepressant use. This
interpretation is supported by studies showing that Med-
icare’s provider reimbursements were 39% higher than
Medicaid’s provider reimbursements, and that providers
were more likely to accept new patients if they were
Medicare enrollees than they were to accept Medicaid
enrollees (Hing, Decker, & Jamoom, 2015; Norton &
Zuckerman, 2000).
The DiD analyses indicated that Medicare Part D
implementation did not affect antidepressant use in
dual eligibles, despite the program’s mandatory cost-
sharing. Although self-reported antidepressant use did
not appear to be disrupted by Medicare Part D
implementation, it is possible that Medicare Part D
drug plans led enrollees to switch to less effective anti-
depressants. Prior research indicated that of dual eli-
gibles who had difficulty accessing a psychiatric
medication following Medicare Part D, 19% were
switched to a different drug because their prescribed
medication was either not covered or not approved
(West et al., 2007).
Moreover, we did not detect a change in depressive
symptoms following Medicare Part D implementation.
Depressive symptoms remained stable in both groups
throughout the study period. Finally, dual eligibles showed
no change in inpatient hospitalization following Medicare
Part D implementation, as the proportion of dual eligibles
being admitted to the hospital remained at about 20%.
Strengths and limitations
WIHS does not collect data on insurance characteristics
and we were unable to examine specific characteristics of
Medicare Part D prescription drug plans, such as utiliz-
ation management tools for antidepressants (Hall,
Kurth, & Moore, 2007). It is possible that study visits
occurring at six-month intervals were too far apart to
detect acute disruptive effects, as identified in prior
studies of medication access. However, given the peri-
odic timing of WIHS data collection, these findings indi-
cate that Medicare Part D did not have a sustained, long-
term effect on antidepressant use, depressive symptoms,
or inpatient hospitalization among dual eligibles. Finally,
WIHS participants may have distinct patterns of self-
reported antidepressant use, depression, and health ser-
vice utilization based on study participation and gender
that limit generalizability to all dual eligible people with
HIV. Despite these limitations, this study has the advan-
tage of data collected independently of insurance status,
medical care engagement, or prescription fill behavior.
These data are a valuable resource for studying medi-
cation access problems, as claims data may selectively
represent people who successfully fill medications.
Conclusions
Coordinating care and managing costs for dual eligibles
is a vital health policy issue. We found that while receiv-
ing the same prescription drug coverage through Medi-
caid in 2005, a greater proportion of dual eligibles used
antidepressants compared to Medicaid-only partici-
pants, despite similar levels of depressive symptoms.
Although prior research has indicated that dual eligible
HIV patients have had difficulty accessing medications
after the transition to Medicare Part D (Das-Douglas
et al., 2009) we identified no such effect on antidepress-
ant use. This analysis also identified no changes in
depressive symptoms or inpatient hospitalization follow-
ing Medicare Part D implementation. These findings
Table 2. Difference-in-differences estimates – average proportion change from pre- to post-Medicare Part D time period, by insurance
type, Women’s Interagency HIV Study, 2003–2008.
Antidepressant use Depressive symptoms (CESD≥ 16) Hospitalization
% SE p-value % SE p-value % SE p-value
Pre-Medicare Part D
Medicaid-only 26.3 44.2 19.4
Dual eligible 33.2 48.0 19.4
Difference +7.0 0.05 0.13 +3.8 0.05 0.46 +0.0 0.03 0.99
Post-Medicare Part D
Medicaid-only 32.8 43.4 19.9
Dual eligible 36.1 46.2 20.6
Difference +3.4 0.05 0.51 +2.8 0.05 0.58 +0.8 0.03 0.81
Difference-in-Differences −3.6 0.04 0.37 −1.0 0.04 0.79 +0.8 0.03 0.81
Abbreviations: CESD, Center for Epidemiologic Studies Depression Scale; SE, Standard Error.
may indicate that protections for psychotropic drug
classes under Medicare Part D were meeting their
intended function in this vulnerable population several
years after implementation. Stable medication use may
also be due to better access to medical care for dual eli-
gibles through Medicare both before and after Medicare
Part D implementation, which may eclipse any effects of
the transition in prescription drug coverage. Even
though this study centers on the 2006 Medicare Part D
implementation, it contributes to contemporary research
in the following ways. During a time when insurance
coverage transitions are a focus of the national healthcare
debate, this study adds to the limited body of knowledge
on how transitioning prescription drug coverage from
Medicaid to Medicare Part D affects mental health-
related service utilization and depressive symptoms in
people with HIV. This study may be especially relevant
to people with HIV as the population of people with
HIV ages in Medicare Part D coverage and the transition
from Medicaid to Medicare Part D becomes more
common.
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